Axiom/Protocols
+ New intake
← Protocols

NAD+

supplementevidence: emerging · v1
Description

NAD+ is a coenzyme central to cellular metabolism, studied extensively in mitochondrial and aging research. Lyophilized powder. Reconstitute with sterile water or BAC water for in-vitro research applications. Store at -20°C. Certificate of Analysis attached to this listing.

Mechanism summary

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. Your body uses it to turn food into cellular energy (ATP), to fuel DNA repair, and to power a family of longevity-related enzymes called sirtuins. [Source: Peptide Dosing Protocols]

How it works

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, playing a crucial role in converting food into cellular energy (ATP), fueling DNA repair, and powering a family of longevity-related enzymes known as sirtuins. The mechanism of action for NAD+ involves its participation in redox reactions, where it alternates between oxidized (NAD+) and reduced (NADH) forms, facilitating the transfer of electrons in metabolic pathways. This process is essential for energy metabolism and the regulation of various biological functions, including cellular repair and maintenance.

Research has shown that NAD+ levels decline with age, which has led to increased interest in NAD+ supplementation as a potential strategy for promoting longevity and enhancing metabolic health. Studies such as those by Yoshino, Baur, and Imai (2018) in Cell Metabolism and Covarrubias et al. (2021) in Nature Reviews Molecular Cell Biology document the biological implications of age-related NAD+ decline. Furthermore, ongoing clinical trials, including NCT07328100 and NCT05243290, aim to expand the understanding of NAD+ in various health contexts, including vascular aging and Gulf War Illness.

While most published human randomized controlled trials (RCTs) focus on oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), limited evidence exists for direct injectable NAD+. Historical case reports and pilot pharmacokinetic studies suggest that intravenous (IV) delivery can rapidly elevate NAD+ levels, but a systematic review in the American Journal of Physiology indicates insufficient high-quality evidence for routine subcutaneous (SubQ) NAD+ practice. Thus, while NAD+ supplementation shows promise, particularly in the context of energy support and recovery, further research is necessary to establish its efficacy and safety in various populations. [Source: Peptide Dosing Protocols]

In plain language

NAD+ is a vital coenzyme that helps convert food into energy and supports DNA repair. It declines with age, leading to interest in its supplementation for health and longevity.

Reference details
Route(s)
Tags
Active
yes
Product details · NJ1000
Price
$95.99
Stock
in stock
Mol. weight
663.4 g/mol
Formula
C21H27N7O14P2
Purity
≥ 99%
CAS #
53-84-9

COA: View certificate (batch TET-4755-a)

Teton Labs product catalog · research-use compound data.

💉 Dosing — 2 references (verbatim from source · not a recommendation)
Dose
250-750 mg per IV session; 300-1000 mg daily for oral precursors (NR/NMN)
Route
oral
Frequency
1-2x weekly IV (loading), monthly (maintenance); daily oral
Duration
4-8 week loading phase IV; ongoing for oral precursors
Reconstitution
Normal saline (0.9% NaCl) 250-500 mL for IV
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 100 mg · Low: 50 mg · High: 200 mg
Route
SubQ
Frequency
2-3x weekly
Duration
4-8 weeks
Cycle
4 weeks, then escalate to 100 mg weekly.
Reconstitution
7.5 mL BAC water for 750 mg vial
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
  • Talk with a licensed clinician before making any health decision.
Safety & side effects
  • Higher side-effect potential; supervised settings only.
  • NAD+ injection is not FDA-approved.
Monitoring & bloodwork
  • CBC at baseline and week 4
Clinical evidence
  • Multiple human RCTs raised blood NAD+ with favorable tolerability. · Nicotinamide Riboside (NR) / 2026
  • A 750 mg single 3-hour infusion has been reported to raise blood NAD+ ~398% over baseline in published pilot work.
  • 60-day dose-response RCT showed dose-dependent NAD+ rise; 600 mg gave the largest effect. · Nicotinamide Mononucleotide (NMN) / 2026
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.

Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.